To provide an overview of the clinical spectrum of GVHD as a complication of HSCT, advances in precision diagnostics, and the current therapeutic landscape.
Key Findings:
GVHD affects approximately 40%-60% of HSCT recipients, with one-third developing higher-grade acute GVHD, as reported in recent studies.
Severe cutaneous presentations of acute GVHD are associated with poor short-term survival, according to clinical data.
Recent data indicates GVHD accounts for a measurable proportion of deaths post-transplant, with specific statistics from CIBMTR.
Interpretation:
The review indicates that while advancements have been made in understanding GVHD and its treatment, challenges in clinical translation remain.
Limitations:
Proposed biomarkers lack harmonized pre-analytic workflows and cross-platform reproducibility, as noted in the literature.
Causal pathways and actionable therapeutic nodes in GVHD remain incompletely defined, highlighting gaps in current research.
Conclusion:
The review emphasizes the need for earlier risk identification and treatment personalization in managing GVHD, based on current findings.
Legend and Kelonia reveal 100 percent response rates in phase 1 trials, dual CAR T opens doors for kidney transplant patients, and iPDSC therapy beefs up failing hearts
